Safety and efficacy of alteplase for restoring function in occluded central venous catheters: Results of the cardiovascular thrombolytic to open occluded lines trial

Journal of Clinical Oncology

Volumn 20, Issue 1, 2002, Pages 317-324

  Deitcher, Steven R ^a   Fesen, Mark R ^a   Kiproff, Paul M ^a   Hill, Patricia A ^a   Li, Xin ^a   McCluskey, Edward R ^a   Semba, Charles P ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; STREPTOKINASE; UROKINASE;

ADOLESCENT; ADULT; AGED; ANAPHYLAXIS; ARTERY DIAMETER; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CENTRAL VENOUS CATHETER; CHILD; CLINICAL TRIAL; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EMBOLISM; FEMALE; FIBRINOLYTIC THERAPY; FLOW MEASUREMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; VASCULAR DISEASE; VEIN BLOOD FLOW; VEIN OCCLUSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTINEOPLASTIC AGENTS; CATHETERIZATION, CENTRAL VENOUS; CATHETERS, INDWELLING; CHILD; CHILD, PRESCHOOL; EQUIPMENT FAILURE; EQUIPMENT SAFETY; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATORS; SURVIVAL ANALYSIS; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0036137741     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.1.317     Document Type: Article

References (16)

1. Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: A double-blind ed, randomized trial
2. Local instillation of small doses of streptokinase for treatment of thrombotic occlusions of long-term access catheters
3. Complications and management of implanted central venous catheters
4. The case of Abbokinase and the FDA: The events leading to the suspension of Abbokinase supplies in the United States
5. Thrombolysis with tissue plasminogen activator in occluded central venous catheters: The COOL-1 efficacy trial results
6. Double-blind placebo-controlled trial of recombinant tissue plasminogen activator for restoration of function in occluded central venous access devices: The Cardiovascular Thrombolytic to Open Occluded Lines (COOL) Efficacy Trial
7. Bioactivity of cryopreserved alteplase solutions
8. Stability and sterility of recombinant tissue plasminogen activator at - 30°C
9. Prevention and management of central venous catheter thrombosis
10. Diagnosis of central venous access device occlusion: Implications for nursing practice
11. Mechanism and management of persistent withdrawal occlusion
12. Recombinant tissue plasminogen activator for central venous access device occlusion
13. Very low doses of warfarin can prevent thrombosis in central venous catheters: A randomized prospective trial
14. Prevention of central venous catheter-associated thrombosis using minidose warfarin in patients with haematological malignancies